RGNX Completes Dosing
REGENXBIO completes dosing in its confirmatory study of RGX-202 gene therapy for Duchenne muscular dystrophy
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
RGNX Completes Dosing
REGENXBIO completes dosing in confirmatory study of RGX-202, marking completion of registrational development program and supporting planned BLA submission in Q3 2026